drugset
drugset / Trial / NCT00045682

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00045682 ↗

Phase 2 Completed 78 enrolled Gynecologic Oncology Group National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2002-09
Primary completion
2006-07-15
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject paclitaxel poliglumex Other / unclassified — Intravenous

Indications

ovarian carcinoma primary peritoneal carcinoma